Benzinga | Mar 23, 2021 06:34AM EDT

Mizuho Initiates Coverage On Freeline Therapeutics with Buy Rating, Announces Price Target of $27

Mizuho analyst Difei Yang initiates coverage on Freeline Therapeutics (NASDAQ:FRLN) with a Buy rating and announces Price Target of $27.